POLD1 and cancer: In this scenario, mutation of POLD1 gene, which has a DNA-proofreading function, is strongly correlated with high mutation load and neo-antigen generation, thus representing a potential marker for predicting the efficacy of IC inhibitor therapy in different types of cancer (51), including SS (50).